Search - tctmd.com

Displaying 81 - 100 of 179

Sort: Relevancy | Date

News Daily News

Early LV Recovery After TAVI Points to Better 5-Year Survival

Yael L. Maxwell

August 01, 2022

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Shelley Wood

July 25, 2022

Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients

Shelley Wood

May 23, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Daily News

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

Caitlin E. Cox

May 03, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

News Conference News THT 2022

LAVA ECMO: Early Data Point to Hemodynamic Benefits, Safety

Caitlin E. Cox

February 02, 2022

Presentation THT 2022

Second Heart -- Enhanced Renal Artery Perfusion for Chronic Heart Failure

Presenter: leslie miller

February 02, 2022

Presentation THT 2022

Revamp - Infra-Renal Vein Partial Occlusion for ADHF

Presenter: Lihu Avitov

February 02, 2022

News Opinion CV Team Dispatch

January 2022 News Roundup

L.A. McKeown

January 01, 2022

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Caitlin E. Cox

December 28, 2021

News Conference News PCR London Valves 2021

Good Results but Small Numbers With JenaValve Trilogy in Severe AR

Michael O'Riordan

November 26, 2021

News Conference News PCR London Valves 2021

Promising Early Results for TriClip in Tricuspid Regurgitation: bRIGHT Registry

Shelley Wood

November 24, 2021

News Conference News AHA 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

Todd Neale

November 17, 2021

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

Shelley Wood

November 14, 2021

Presentation TCT 2021

Manipulation of Renal Preload and Afterload for Acute Decompensated Heart Failure

Presenter: Navin Kapur

November 06, 2021

News Conference News ESC 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

Todd Neale

August 27, 2021

News Daily News

Studies Explore Post-MI Use of Beta-blockers, Mineralocorticoid Receptor Antagonists

Todd Neale

July 09, 2021

News Opinion CV Team Dispatch

June 2021 News Roundup

L.A. McKeown

June 01, 2021

Advertisement

Early LV Recovery After TAVI Points to Better 5-Year Survival

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients

Dapagliflozin Boosts Health Status Across LVEF Range

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Guideline-Directed Therapies Underused in Frail HF Patients

LAVA ECMO: Early Data Point to Hemodynamic Benefits, Safety

Second Heart -- Enhanced Renal Artery Perfusion for Chronic Heart Failure

Revamp - Infra-Renal Vein Partial Occlusion for ADHF

January 2022 News Roundup

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Good Results but Small Numbers With JenaValve Trilogy in Severe AR

Promising Early Results for TriClip in Tricuspid Regurgitation: bRIGHT Registry

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

Manipulation of Renal Preload and Afterload for Acute Decompensated Heart Failure

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

Studies Explore Post-MI Use of Beta-blockers, Mineralocorticoid Receptor Antagonists

June 2021 News Roundup

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content